Four Cartons That Won't Verify
A Nevada independent pharmacy receives a 10-carton shipment of insulin glargine 100 units/mL pens from its primary wholesaler. The receiving technician scans the 2D DataMatrix barcodes and the pharmacy's DSCSA system flags four cartons: the serial numbers on two cartons duplicate serials already recorded from a shipment three weeks earlier, one carton's lot number does not match the lot on the wholesaler's advance ship notice, and one carton has a broken tamper seal with pen caps loose inside. The product looks normal. The wholesaler's customer service line says the mismatch is "probably a labeling glitch - just dispense it, it's insulin and patients need it." The pharmacy has 22 patients on this product and two are out of pens. The technician asks whether he can shelve the four cartons and "verify them later" so the filling queue does not back up.
1. What must the pharmacy do with the four cartons, and why is "verify later" not an acceptable plan?
Read the worked answer
Treat all four cartons as suspect product and stop them from moving immediately. Under DSCSA (21 U.S.C. 360eee-1), a dispenser that encounters suspect product - a serial number that duplicates an earlier shipment, a lot that does not match transaction data, a broken seal - must quarantine the product, investigate, and refrain from distributing or dispensing it until it is cleared. Shelving it "until later" fails because the entire control depends on physical segregation: the cartons would be indistinguishable from verified stock at 2 a.m., during a shift change, or by a technician covering a different station. Label each carton "DO NOT DISPENSE - SUSPECT PRODUCT," date it, and secure it in a separate, locked location. Request verification from the trading partner that supplied it; trading partners must respond to verification requests within 24 hours. Notify the wholesaler in writing - not by phone alone - that the product is suspect, and do not return it to the supply chain until directed, because an unverified return is exactly how illegitimate product re-enters distribution. A broken seal alone justifies quarantine. The insulin shortage is a real pressure, but it is not a legal basis to release unverified product.
2. The investigation concludes that two cartons are counterfeit. What notifications are required, to whom, and on what timeline?
Read the worked answer
Illegitimate product triggers a 24-hour notification duty. Once the pharmacy determines the product is counterfeit (or diverted, stolen, or otherwise illegitimate), it must notify FDA within 24 hours using Form FDA 3911, and notify immediate trading partners - here the wholesaler and any other pharmacy or distributor known to have received the same lot - within 24 hours as well. If later testing or the wholesaler clears the product, a termination notification should follow so the record closes. Document everything: who found what, when, the serials, the lot, photographs, the quarantine location, and every call and email. DSCSA records must be retained for six years. Note the interaction with FDA's enforcement exemptions for small dispensers: those exemptions address certain transaction-data exchange obligations, not the duty to quarantine suspect product and notify FDA of illegitimate product, which applies regardless of size. Separately, if the counterfeit product turns out to be a controlled substance (it is not here), report theft or significant loss to DEA on Form 106 and notify the state board.
3. Before the flag appeared, two pens from the flagged cartons were already dispensed to a patient. What should happen now?
Read the worked answer
This becomes a patient safety event, not just an inventory problem. First identify exactly who received the product - patient name, prescriber, date, quantity, lot, and serial - using the dispensing record and the transaction data. Then notify the prescriber and contact the patient directly, explaining what is known and what is not; do not wait for the investigation to finish. Advise the patient to stop using the pens pending assessment and offer a replacement supply from verified stock (or direct them to another pharmacy if none is verified). Because insulin is a refrigerated injectable, counterfeit product raises questions about identity, potency, and cold chain, so the safe assumption is that the product cannot be trusted. File a MedWatch report on the adverse event or product problem, cooperate with FDA's investigation, and keep the notification records. Finally, review why two pens left the pharmacy before verification - the workflow let scanning lag behind dispensing, which is the root cause worth fixing.